Impact of potential pregabalin or duloxetine drug–drug interactions on health care costs and utilization among Medicare members with fibromyalgia
Jeffrey J Ellis,1 Alesia B Sadosky,2 Laura L Ten Eyck,1 Joseph C Cappelleri,2 Courtney R Brown,3 Brandon T Suehs,1 Bruce Parsons2 1Comprehensive Health Insights Inc., Louisville, KY, USA; 2Pfizer Inc., New York, NY, USA; 3Humana Inc., Louisville, KY, USA Purpose: To examine the impact of newly init...
Main Authors: | Ellis JJ, Sadosky AB, Ten Eyck LL, Cappelleri JC, Brown CR, Suehs BT, Parsons B |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-10-01
|
Series: | ClinicoEconomics and Outcomes Research |
Online Access: | http://www.dovepress.com/impact-of-potential-pregabalin-or-duloxetine-drugndashdrug-interaction-peer-reviewed-article-CEOR |
Similar Items
-
Real-world comparison of health care utilization between duloxetine and pregabalin initiators with fibromyalgia
by: Peng X, et al.
Published: (2014-01-01) -
Comparing common reasons for inpatient and outpatient visits between commercially-insured duloxetine or pregabalin initiators with fibromyalgia
by: Zhao Y, et al.
Published: (2012-10-01) -
Duloxetine for the management of fibromyalgia syndrome
by: Beth A Scholz, et al.
Published: (2009-07-01) -
Duloxetine and pregabalin in neuropathic pain of lung cancer patients
by: Şule Karabulut Gül, et al.
Published: (2020-03-01) -
Pregabalin for the management of fibromyalgia syndrome
by: Chad S Boomershine
Published: (2010-06-01)